Dario Eklund, Santhera CEO

San­thera’s va­morolone bags FDA ap­proval for Duchenne af­ter long jour­ney

Swiss biotech San­thera has at last won FDA ap­proval for its steroidal drug va­morolone to treat boys and men with Duchenne mus­cu­lar dy­s­tro­phy, with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.